Futures Dip Ahead Of Private Payrolls Data, After Hawkish Surprise Out Of New Zealand
Futures Dip Ahead Of Private Payrolls Data, After Hawkish Surprise Out Of New Zealand
…
125,525€
0,82%
Echtzeit-Aktienkurs AstraZeneca PLC
Bid:
Ask:
Nachrichten zur AstraZeneca PLC Aktie
UK court orders GSK to pay AstraZeneca royalties on total sales of Zejula
...(Reuters) - A UK court on Wednesday ordered GSKs Tesaro to pay......…
Form 6-K ASTRAZENECA PLC For: Apr 05
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
AstraZeneca Imfinzi, Lynparza combo improves progression-free survival in ovarian cancer trial
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AstraZeneca drug combo improves ovarian cancer survival rate
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…
AstraZeneca: Lynparza Combination Improves PFS In Phase III Ovarian Cancer Trial
LONDON (dpa-AFX) - British drug major AstraZeneca Plc (AZN, AZN.L) said results from an interim analysis of the DUO-O Phase…
RPT-UPDATE 1-AstraZeneca says drug combo meets goal in late-stage ovarian cancer trial
... (Reuters) - AstraZeneca on Wednesday
said a combination of its cancer......…
UPDATE 1-AstraZeneca says drug combo meets goal in late-stage ovarian cancer trial
...(Adds detail on analysis, background on Lynparza)
April 5 (Reuters......…
AstraZeneca says cancer drug combination meets late-stage trial goal
...April 5 (Reuters) - AstraZeneca said on
Wednesday a combination......…
Drug giant AstraZeneca teams up with Hong Kong Science Park to drive biotech, medical research growth
The latest collaboration will involve AstraZeneca and HKSTP providing services to overseas and mainland Chinese start-ups under the park’s incubation…
Astrazeneca (AZN) Gains As Market Dips: What You Should Know
Astrazeneca (AZN) closed the most recent trading day at $70.25, moving +0.49% from the previous trading session....…
Form 6-K ASTRAZENECA PLC For: Apr 03
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
AstraZeneca (AZN) Ultomiris Gets CHMP Nod for New Rare Disease
CHMP recommends AstraZenecas (AZN) Ultomiris for the treatment of patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive....…
Total Voting Rights
3 April 2023 15:00 BST
Transparency Directive
Voting rights and capital
The following notification is made in accordance with the UK Financial Conduct…
AstraZeneca: CHMP Recommendes Ultomiris For EU Approval For Neuromyelitis Optica Spectrum Disorde
LONDON (dpa-AFX) - British drug major AstraZeneca PLC (AZN, AZN.L) announced Monday that the Committee for Medicinal Products for Human…
AstraZeneca Ultomiris gets EMA backing for expanded use
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 6-K ASTRAZENECA PLC For: Mar 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Risk Of Cardiac Death Tripled For Young Women Following AstraZeneca COVID-19 Vaccination: Study
Risk Of Cardiac Death Tripled For Young Women Following AstraZeneca COVID-19 Vaccination: Study
…
AstraZeneca signs exclusive global license deal with KYM Biosciences
Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…
AstraZeneca Completes KYM Solid Tumors Treatment Deal
AstraZeneca Completes KYM Solid Tumors Treatment Deal...…
AstraZeneca completes KYM agreement for CMG901
30 March 2023 07:00 BST
License agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate, completed
AstraZeneca has completed an…
Astrazeneca (AZN) Gains But Lags Market: What You Should Know
In the latest trading session, Astrazeneca (AZN) closed at $68.64, marking a +0.06% move from the previous day....…
AstraZeneca Axes Pneumonia Drug Pact With Aridis
AstraZeneca plc (NASDAQ: AZN) scrapped its license agreement with Aridis Pharmaceuticals Inc (NASDAQ: ARDS).
read more...…
Salipro Biotech publishes research in Scientific Reports on structure-function studies for membrane proteins in collaboration with AstraZeneca
Stockholm, March 28, 2023 – Salipro Biotech today announces the publication of results from a collaboration with AstraZeneca. The study…
AstraZeneca Unusual Options Activity
read more...…
AstraZeneca Reports Positive High-level Results From Phase 3 Study Of Eplontersen
LONDON (dpa-AFX) - AstraZeneca plc (AZN.L) Monday said its investigational drug eplontersen showed sustained benefit in NEURO-TTRansform Phase 3 study…
Ionis, AstraZeneca report positive outcomes from eplontersen trial
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 6-K ASTRAZENECA PLC For: Mar 27
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
TOP NEWS: AstraZeneca hails eplontersen; Enhertu wins another approval
Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…
UPDATE 1-UK stocks start the week higher as banks, AstraZeneca climb
...(For a Reuters live blog on U.S., UK and European stock
markets... updates prices, details)
By Johann M Cherian
March 27 (Reuters)…
Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know
Astrazeneca (AZN) closed the most recent trading day at $67.26, moving +1.04% from the previous trading session....…
Freedom Finance Börsenfrühstück - "Risikosteuerung mit dem Beta-Faktor" - Langweilig? Aber nicht die Rendite...
Mit dem Beta-Faktor können Anleger das Risiko in ihrem Depot in gewissen Grenzen steuern. Beta gibt Aufschluss darüber, ob sich…
Form 6-K ASTRAZENECA PLC For: Mar 22
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
José-Baselga-Forschungsfonds gibt erstmalige Förderung der Prionenforschung bekannt
BOSTON (USA)--(BUSINESS WIRE)--Der José-Baselga-Forschungsfonds (JBRF), der von Alexion, AstraZeneca Rare Disease, unterstützt wird, gab heute die erstmalige Vergabe des Global…
Astrazeneca (AZN) Stock Moves -0.56%: What You Should Know
In the latest trading session, Astrazeneca (AZN) closed at $65.61, marking a -0.56% move from the previous day....…
P/E Ratio Insights for AstraZeneca
read more...…
AstraZeneca (AZN) Stock Up 5% in a Year: What Awaits in 2023?
AstraZeneca (AZN) expects total revenues to increase in the low-to-mid single-digit percentage in 2023 at CER....…
Astrazeneca (AZN) Gains As Market Dips: What You Should Know
Astrazeneca (AZN) closed the most recent trading day at $65.18, moving +1.54% from the previous trading session....…
AstraZeneca (AZN) Posts Positive Data From Lung Cancer Studies
Data from late-stage label expansion studies show that AstraZenecas (AZN) cancer drugs are effective for treating non-small cell lung cancer…
AstraZeneca Neutral
ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Astrazeneca auf "Neutral" mit einem Kursziel von 11900 Pence belassen. Die…
Zacks Industry Outlook Highlights J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi
J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi have been highlighted in this Industry Outlook article....…
Form 6-K ASTRAZENECA PLC For: Mar 09
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
AstraZeneca hails trial results of cancer drugs Imfinzi and Tagrisso
Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…
AstraZeneca Tagrisso improves overall survival in lung cancer patients in phase 3 trial
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Astrazeneca meldet positive Studienergebnisse mit Imfinzi bei NSCLC
Von Joe Hoppe LONDON (Dow Jones)--Astrazeneca hat mit seinem monoklonalen Antikörper Durvalumab einen Erfolg in einer klinischen Phase-3-Studie erzielt.…
AstraZeneca Imfinzi Phase 3 Trial Returns Positive Results
AstraZeneca Imfinzi Phase 3 Trial Returns Positive Results...…
UPDATE 1-AstraZeneca says cancer drug Imfinzi improves survival chances in late-stage trial
...(Adds detail on trial, quote and background)
March 9 (Reuters) - Lung......…
AstraZeneca says cancer drug Imfinzi improves survival rates in late-stage trial
...March 9 (Reuters) - Drugmaker AstraZeneca said
on Thursday a late......…
Imfinzi improved EFS in resectable lung cancer
9 March 2023 07:00 GMT
Imfinzi significantly improved event-free survival in AEGEAN
Phase III trial for patients with resectable non-small cell lung cancer
Results…
Director/PDMR Shareholding
8 March 2023 11:01 GMT
Transactions by Persons Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announced that, on 4 March 2023, certain…